Isis Pharmaceuticals to Provide Update on FDA Approval of KYNAMRO, 09:30 AM ET, Wednesday, January 30, 2013
Isis Pharmaceuticals (NASDAQ: ISIS) announced today that it will conduct a conference call and webcast to provide an update on the U.S. Food and Drug Administration (FDA) approval of the marketing of KYNAMRO™ (mipomersen) for the treatment of patients with Homozygous Familial Hypercholesterolemia (HoFH).
CONFERENCE CALL At 09:30 a.m. Eastern Time, Wednesday, January 30, 2013, Isis will conduct a live audio webcast and conference call. Interested parties may listen to the call by dialing 1-866-323-2841, or 1-617-500-8943 for international callers, and refer to conference ID 95497110. The webcast can be accessed at www.isispharm.com. A webcast replay will be available for a limited time at the same address.
ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH. Genzyme is also